Using mouse models of AD, they demonstrated that PD-1 blockade, achieved through injection of a PD-1-specific blocking antibody, elicited an interferon (IFN)-γ-dependent systemic immune response. This evidence concerns the gene PDCD1 and Alzheimer disease.